Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property

CRANBURY, N.J., June 6, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial …

Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property Read More »